FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912298384> ?p ?o ?g. }

• W2912298384 endingPage "S1477" @default.
• W2912298384 startingPage "S1477" @default.
• W2912298384 abstract "Introduction: Uztekinumab blocks interleukins 12 and 23 through their common p40 subunit and has been previously used in the U.S. for the treatment of plaque psoriasis and psoriatic arthritis. It just recently got FDA approval for treatment of patients with moderate to severe Crohn's disease refractory to one or more Anti TNF-α after promising results from three pivotal phase 3 clinical trials with over 1300 patients. Our study aims to assess the effectiveness and safety of uztekinumab in refractory patients with Crohn's in real-life practice on our population. Methods: A retrospective chart review was performed with inclusion criteria of patients with Crohn's disease refractory to Anti TNF-α therapy and currently on uztekinumab. Demographic factors including age, sex, onset of disease with duration were gathered. Treatments previously received and number of surgeries were used to gauge disease severity. Remission was defined as lack of diarrhea, rectal bleeding, abdominal pain, nausea, vomiting. Data for side-effects of uztekinumab was also gathered. Results: There were a total of 5 patients: 2 were females and 3 were males. The age of onset ranged from 13-34 years with disease duration ranging from 15-25 years. All patients received a minimum of 3 months of therapy with one patient on uztekinumab for over 2 years. Induction therapy that was weight based starting 0, 4 and 16 weeks followed by maintenance of every 12 weeks was used on all patients. All of these patients could be classified as severe given all of them received at least one major surgery including proctocolectomy, Ileal resection, diverting ileostomy, ileocolectomy and had failed multiple medications (as mentioned on table 1). All our patients achieved clinical remission with 3 completely off steroids and 2 being tapered of steroids. Three patients had peri-anal disease with improvement after the start of therapy. Uztekinumab was tolerated well with no side-effects noted including opportunistic infections, allergic reactions, neurologic and cardiovascular side-effects. Conclusion: Uztekinumab which is just recently FDA approved is showing promising results in our series of patients. It should be strongly considered on patients refractory of Anti TNF-α therapy as it is able to achieve IBD quality measures with steroid sparing therapy and improved bone health which ultimately improves overall patient outcomes and quality of life.Table: Table. Patient characteristic and their outcomes" @default.
• W2912298384 created "2019-02-21" @default.
• W2912298384 creator A5000974914 @default.
• W2912298384 creator A5001042761 @default.
• W2912298384 creator A5019372025 @default.
• W2912298384 creator A5038808879 @default.
• W2912298384 creator A5049409962 @default.
• W2912298384 date "2017-10-01" @default.
• W2912298384 modified "2023-09-26" @default.
• W2912298384 title "Case Series of Crohnʼs Disease Patients Refractory to Anti-TNF Alpha Therapy on Uztekinumab" @default.
• W2912298384 doi "https://doi.org/10.14309/00000434-201710001-02720" @default.
• W2912298384 hasPublicationYear "2017" @default.
• W2912298384 type Work @default.
• W2912298384 sameAs 2912298384 @default.
• W2912298384 citedByCount "0" @default.
• W2912298384 crossrefType "journal-article" @default.
• W2912298384 hasAuthorship W2912298384A5000974914 @default.
• W2912298384 hasAuthorship W2912298384A5001042761 @default.
• W2912298384 hasAuthorship W2912298384A5019372025 @default.
• W2912298384 hasAuthorship W2912298384A5038808879 @default.
• W2912298384 hasAuthorship W2912298384A5049409962 @default.
• W2912298384 hasConcept C121332964 @default.
• W2912298384 hasConcept C126322002 @default.
• W2912298384 hasConcept C141071460 @default.
• W2912298384 hasConcept C142424586 @default.
• W2912298384 hasConcept C16005928 @default.
• W2912298384 hasConcept C2778260677 @default.
• W2912298384 hasConcept C2779134260 @default.
• W2912298384 hasConcept C2779280984 @default.
• W2912298384 hasConcept C2780564577 @default.
• W2912298384 hasConcept C2780580376 @default.
• W2912298384 hasConcept C2780852908 @default.
• W2912298384 hasConcept C2780955771 @default.
• W2912298384 hasConcept C2908647359 @default.
• W2912298384 hasConcept C71924100 @default.
• W2912298384 hasConcept C87355193 @default.
• W2912298384 hasConcept C90924648 @default.
• W2912298384 hasConcept C99454951 @default.
• W2912298384 hasConceptScore W2912298384C121332964 @default.
• W2912298384 hasConceptScore W2912298384C126322002 @default.
• W2912298384 hasConceptScore W2912298384C141071460 @default.
• W2912298384 hasConceptScore W2912298384C142424586 @default.
• W2912298384 hasConceptScore W2912298384C16005928 @default.
• W2912298384 hasConceptScore W2912298384C2778260677 @default.
• W2912298384 hasConceptScore W2912298384C2779134260 @default.
• W2912298384 hasConceptScore W2912298384C2779280984 @default.
• W2912298384 hasConceptScore W2912298384C2780564577 @default.
• W2912298384 hasConceptScore W2912298384C2780580376 @default.
• W2912298384 hasConceptScore W2912298384C2780852908 @default.
• W2912298384 hasConceptScore W2912298384C2780955771 @default.
• W2912298384 hasConceptScore W2912298384C2908647359 @default.
• W2912298384 hasConceptScore W2912298384C71924100 @default.
• W2912298384 hasConceptScore W2912298384C87355193 @default.
• W2912298384 hasConceptScore W2912298384C90924648 @default.
• W2912298384 hasConceptScore W2912298384C99454951 @default.
• W2912298384 hasLocation W29122983841 @default.
• W2912298384 hasOpenAccess W2912298384 @default.
• W2912298384 hasPrimaryLocation W29122983841 @default.
• W2912298384 hasRelatedWork W2090023464 @default.
• W2912298384 hasRelatedWork W2315082114 @default.
• W2912298384 hasRelatedWork W2320562621 @default.
• W2912298384 hasRelatedWork W2372392032 @default.
• W2912298384 hasRelatedWork W2387364079 @default.
• W2912298384 hasRelatedWork W3041734402 @default.
• W2912298384 hasRelatedWork W3048457546 @default.
• W2912298384 hasRelatedWork W3133328946 @default.
• W2912298384 hasRelatedWork W3142684436 @default.
• W2912298384 hasRelatedWork W3217631918 @default.
• W2912298384 hasVolume "112" @default.
• W2912298384 isParatext "false" @default.
• W2912298384 isRetracted "false" @default.
• W2912298384 magId "2912298384" @default.
• W2912298384 workType "article" @default.